



## Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 16, 2025

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 16, 2025-- [Stoke Therapeutics, Inc.](https://www.stoketherapeutics.com) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2025, it granted stock options to purchase an aggregate of 195,800 shares of common stock to ten new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of \$35.60 per share, which is equal to the closing price of Stoke's common stock on September 15, 2025. Each option will vest over a 4-year period, with 1/4<sup>th</sup> of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48<sup>th</sup> of the shares underlying each employee's option over the following 36 months, subject to the employee's continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

### About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit <https://www.stoketherapeutics.com/>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251016067722/en/): <https://www.businesswire.com/news/home/20251016067722/en/>

### Stoke Media & Investor Contacts:

Dawn Kalmar  
Chief Communications Officer  
[dkalmar@stoketherapeutics.com](mailto:dkalmar@stoketherapeutics.com)  
781-303-8302

Doug Snow  
Director, Communications & Investor Relations  
[IR@stoketherapeutics.com](mailto:IR@stoketherapeutics.com)  
508-642-6485

Source: Stoke Therapeutics, Inc.